Fierce Pharma

SEPTEMBER 6, 2023

IBM disclosed "unauthorized access" to J&J’s Janssen CarePath patient assistance program, which helped over 1 million U.S. patients last year.

Patients 327

Patients 327

MedCity News

SEPTEMBER 6, 2023

Gene therapy biotech Kriya Therapeutics has acquired Tramontane Therapeutics, a startup focused on metabolic diseases. Tramontane brings a gene therapy that’s a potential one-time treatment for the fatty liver disease NASH.

Biopharma 113

Biopharma Pharma 113

Fierce Pharma

SEPTEMBER 6, 2023

Expecting to be subject to Medicare pricing negotiations, Astellas in July challenged the legality of the Inflation Reduction Act (IRA). | Expecting to be subject to Medicare pricing negotiations, Astellas in July challenged the legality of the Inflation Reduction Act. But now that the Centers for Medicare & Medicaid Services has released the first 10 drugs set for governmental bargaining, the company is ready to abandon its litigation.

270

270

MedCity News

SEPTEMBER 6, 2023

Drug developers need policies and technological infrastructure to execute on their goal of being patient-focused. At a minimum, this means a compliant way to engage patients and truly hear their voices; at its most effective, patient engagement also meets patients where they are – whenever and wherever that may be.

Patients 108

Patients Biopharma 108

Advertisement

Distribution

Fierce Pharma

SEPTEMBER 6, 2023

AstraZeneca’s Ultomiris expansion plan has hit a snag in the U.S. | The FDA handed the company a complete response letter for its Ultomiris application in neuromyelitis optica spectrum disorder, a rare autoimmune disease affecting the central nervous system.

FDA 240

FDA 240

MedCity News

SEPTEMBER 6, 2023

Integral raked in $6.9 million in seed funding in this week. The San Francisco-based startup is developing technology that seeks to speed up the process of exchanging sensitive health data while still maintaining robust privacy protection.

Healthcare 104

Healthcare Healthcare 104

MedCity News

SEPTEMBER 6, 2023

Pitango Venture Capital, one of the largest venture capital firms in Israel, announced the first closing of a new $175 million healthcare technology fund. With the new fund, the firm plans to build a portfolio of approximately 15 new companies over a period of three to four years.

Healthcare 101

Healthcare Healthcare 101

Fierce Pharma

SEPTEMBER 6, 2023

Just as Novartis’ C-suite appeared to have stabilized amid a major overhaul of the company, the Swiss pharma is losing its international markets leader and getting rid of its chief commercial offic | Just as Novartis’ C-suite appeared to have stabilized amid a major overhaul of the company, the Swiss pharma is losing its international markets leader and getting rid of its chief commercial officer title.

Pharma 218

Pharma Marketing 218

MedCity News

SEPTEMBER 6, 2023

In a day of vast innovation, expansion, and acquisitions, an engineering mindset can bring a unique and effective approach to thinking across the system, evaluating the current and future state, standardizing on best practices, and considering upstream and downstream workflows.

Engineering 101

Engineering Patients 101

Fierce Pharma

SEPTEMBER 6, 2023

Royalty Pharma, a company known for ponying up chunks of cash in exchange for long-term drug royalties, has hopped on board with Ascendis Pharma's long-acting growth hormone Skytrofa. | Ascendis hopes to bring its second TransCon product to the market and overcome manufacturing issues. Meanwhile, the company's Skytrofa is going up against a new competitor in Pfizer and OPKO Health's Ngenla.

Manufacturing 211

Manufacturing Pharma FDA Marketing 211

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

MedCity News

SEPTEMBER 6, 2023

Precision medicine for neurodegenerative conditions has the potential to radically change the way patients are treated and managed over time. As an industry, we must continue to expand our thinking and push the boundaries of science, technology, and data analytics to capture precision medicine opportunities in broader areas of unmet medical needs.

Management 97

Management Medicine Medical Patients 97

PharmExec

SEPTEMBER 6, 2023

A phased launch approach may ultimately be more sustainable and enable maximum market penetration and commercial success with less upfront investment than traditional “go-for-broke” strategies.

Marketing 98

Marketing 98

MedCity News

SEPTEMBER 6, 2023

The Centers for Medicare and Medicaid Services has announced two value-based care alternative payment models set to launch in July 2024, one focused on dementia and one on primary care.

85

85

Pharmaceutical Technology

SEPTEMBER 6, 2023

The UK MHRA has granted approval for Pfizer and BioNTech’s adapted Covid-19 vaccine (Comirnaty) targeting the Omicron XBB 1.5 subvariant.

98

98

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

PharmaTimes

SEPTEMBER 6, 2023

Therapy is used among adult patients with symptomatic obstructive hypertrophic cardiomyopathy - News - PharmaTimes

Patients 107

Patients 107

European Pharmaceutical Review

SEPTEMBER 6, 2023

A report published by Lucintel predicts that the global Raman spectroscopy market will value $875.2 million by 2028, with a CAGR of 7.3 percent from 2023 to 2028. Between 2023 to 2028, the research suggested that a greater focus on drug development, growing requirement for spectroscopy via cloud-based platforms, alongside the industry’s need for precise and effective analytical methods, will drive the market.

Marketing 84

Marketing Distribution Pharmaceutical products Media 84

PharmaVoice

SEPTEMBER 6, 2023

Murray McKinnon, CSO of Empress Therapeutics, believes its drug discovery platform holds the key to treating and detecting many diseases.

97

97

PharmaTimes

SEPTEMBER 6, 2023

Technology combines AI-based, ultrasound-guided 3D reconstruction with robotic needle insertion - News - PharmaTimes

105

105

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

European Pharmaceutical Review

SEPTEMBER 6, 2023

The recommendation of Camzyos ® ▼(mavacamten) as an add-on treatment option for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults has been published in the National Institute for Health and Care Excellence (NICE)’s final guidance. Bristol Myers Squibb’s first-in-class treatment option is recommended for eligible oHCM patients on the NHS.

Consulting 80

Consulting Management Patients Marketing 80

Pharmaceutical Technology

SEPTEMBER 6, 2023

The US FDA has requested that AstraZeneca make modifications to the Ultomiris REMS programme to approve a label expansion.

FDA 98

FDA 98

Pharmaceutical Commerce

SEPTEMBER 6, 2023

Stakeholders uncover the obstacles surrounding the industry onboarding process.

105

105

Pharma Marketing Network

SEPTEMBER 6, 2023

“Artificial Intelligence” (AI) is certainly experiencing the shiny object spotlight in 2023. In all industries, the “what if’s” around the use of AI range from massive upsides in efficiency to looming downsides of impending elimination of entire teams. At the DHC Group, our goal to help shape the future of digital health means we focus on upcoming challenges and industry advancements, and provide insights to help prepare decision makers for the evolving digital health landscape.

Healthcare 64

Healthcare Healthcare Physicians Ethics 64

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization

PharmExec

SEPTEMBER 6, 2023

Disruptive strategies are essential to grow the pharma industry.

Pharma 98

Pharma 98

Pharma Marketing Network

SEPTEMBER 6, 2023

“Artificial Intelligence” (AI) is certainly experiencing the shiny object spotlight in 2023. In all industries, the “what if’s” around the use of AI range from massive upsides in efficiency to looming downsides of impending elimination of entire teams. At the DHC Group, our goal to help shape the future of digital health means we focus on upcoming challenges and industry advancements, and provide insights to help prepare decision makers for the evolving digital health landscape.

Healthcare 52

Healthcare Healthcare Physicians Ethics 52

Contrarian Sales Techniques

SEPTEMBER 6, 2023

We're on the cusp of entering the most thrilling time for businesses worldwide - the fourth quarter, or as many in the business realm affectionately call it, the Q4. For those not deeply entrenched in the business world, think of this period as the Super Bowl or the World Cup. The stakes are high, the atmosphere is electric, and the playing field is rife with opportunities.

Training 52

Training Marketing Sales Strategy Sales 52

PharmaTech

SEPTEMBER 6, 2023

Further expansions of the pharmaceutical development and manufacturing services of ten23 are happening at the BASE and VIVA facilities to continue to support complex sterile product development, testing, and manufacturing.

Manufacturing 52

Manufacturing Pharmaceutical 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

Progressive Medical

SEPTEMBER 6, 2023

Delivering Innovative Infusion Therapy and Improving Patient Outcomes PMI is proud to partner with Asset Medical to offer a portfolio […] The post Progressive Medical, Inc. and Asset Medical Join Forces appeared first on Progressive Medical, Inc.

Medical 52

Medical Patients 52

Legacy MEDSearch

SEPTEMBER 6, 2023

Abbott (NYSE: ABT ) and Bigfoot Biomedical today announced a definitive agreement for Abbott to acquire Bigfoot, a leader in developing smart insulin management systems for people with diabetes. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2023. Financial terms were not disclosed. Abbott and Bigfoot have worked together on connected diabetes solutions since 2017.

Healthcare Provider 52

Healthcare Provider Recruitment Healthcare Healthcare 52

PharmaTech

SEPTEMBER 6, 2023

The focus in labs is leaning more heavily toward automated processes while at the same time maintaining efficiency, safety, and a personalized experience for the lab worker.

Safety 52

Safety 52

PharmExec

SEPTEMBER 6, 2023

The implications of Twitter’s rebrand for healthcare marketing.

Pharma 85

Pharma Healthcare Healthcare Marketing 85

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Management